solute carrier family 29 member 2Genealiases: DER12 · ENT2 · HNP36 · hENT2
Q-omics provides the consensus-scored SLC29A2 profile across patient tissues and cancer cell-line models. SLC29A2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC29A2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SLC29A2 RNA expression shows 18,836 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where SLC29A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC29A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC29A2 survival associations across molecular data types. SLC29A2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC29A2 RNA expression–survival associations across cancer types. High SLC29A2 expression shows unfavorable associations in MESO, ACC, LAML, UCEC and BLCA, but favorable associations in UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC29A2 RNA expression.
This table summarizes SLC29A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC29A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC29A2 shows lower tumor expression in KIRC and higher tumor expression in BLCA, COAD, STAD, LIHC and UCEC. The KIRC box plot shows higher SLC29A2 RNA expression in normal versus tumor tissue (log2 FC = −2.440, t-test p < 0.001).
This table shows molecular features associated with SLC29A2 in patient tissues and cancer cell lines. In patient samples, SLC29A2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC29A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
